words lines 0 60 0 20 top 50% bottom top 1 0 0 .22 back 1 0 .001 1 .1 1.5 none top bottom center center true 1 none top top center top true 0 200 .001 none
top bottom top center true 1 none top bottom bottom bottom true 1 none

Uncategorized

Juniper Biologics Establishes Global Headquarters in Singapore 

By Juniper Biologics / September 15, 2022 / Comments Off on Juniper Biologics Establishes Global Headquarters in Singapore 

Juniper Biologics’ investment will support the growth and innovation of Singapore’s pharmaceutical sector  15 Sept 2022, Singapore:  Juniper Biologics, a science-led speciality healthcare company focused on commercialising novel therapies, today announced the establishment of its Global Headquarters in Singapore, from where the Company will continue the expansion of its global operations. This announcement was supported by … Read more

Read More

Helsinn Healthcare SA signs exclusive license agreement with Juniper Biologics Pte. Ltd. for LEDAGA® (chlormethine) in Australia, Asia and the Middle East*

By Juniper Biologics / September 1, 2022 / Comments Off on Helsinn Healthcare SA signs exclusive license agreement with Juniper Biologics Pte. Ltd. for LEDAGA® (chlormethine) in Australia, Asia and the Middle East*

Lugano, Switzerland, September 1, 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and Juniper Biologics Pte Ltd, a science-led healthcare company focused on researching, developing and commercializing novel therapies, announced today the signing of an exclusive distribution license and … Read more

Read More

Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets*

By Juniper Biologics / May 4, 2022 / Comments Off on Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets*

Juniper Biologics Pte Ltd announced today the signing of an exclusive license agreement to develop and commercialise infigratinib (INN) in Australia, New Zealand, Southeast Asia and certain markets in the Middle East and Africa.

Read More

Juniper Biologics Acquires Cell-Mediated Gene Therapy TG-C LD For Treatment of Knee Osteoarthritis

By Juniper Biologics / April 13, 2022 / Comments Off on Juniper Biologics Acquires Cell-Mediated Gene Therapy TG-C LD For Treatment of Knee Osteoarthritis

$600 million USD acquisition will see Juniper Biologics offer the world’s first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa.

Read More

Juniper Biologics In-Licenses Helsinn’s Oncology Portfolio For Aloxi®, Onicit®, Paloxi®, Akynzeo® and Anamorelin (INN)

By Juniper Biologics / December 22, 2021 / Comments Off on Juniper Biologics In-Licenses Helsinn’s Oncology Portfolio For Aloxi®, Onicit®, Paloxi®, Akynzeo® and Anamorelin (INN)

Helsinn Healthcare SA announced the signing of exclusive distribution, license and supply agreements for Aloxi®, Onicit®, Paloxi®, Akynzeo® (IV and oral formulations) and anamorelin (INN).

Read More

Juniper Biologics Announces the Appointment of Raman Singh as Chief Executive

By Juniper Biologics / April 22, 2021 / Comments Off on Juniper Biologics Announces the Appointment of Raman Singh as Chief Executive

Juniper Biologics has announced the appointment of celebrated pharmaceutical executive Raman Singh to the role of Chief Executive.

Read More